SAN DIEGO, Nov. 8 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN),
developer of advanced diagnostic products, announced today it was issued
Patent No. 6,960,298, "Mesoporous permeation layers for use on active
electronic matrix devices" by the U.S. Patent and Trademark Office. The '298
patent relates to synthetic polymer hydrogels with defined pore size that
overlay an electrode on a substrate. The technology, which is an integral
component of the NanoChip(R) Electronic Microarray, provides high-performance
characteristics on active electronic chip devices, offering a protective
interface between the electrically active surface on the NanoChip(R) array and
the biological test environment.
Ion-permeable permeation layers are essential to the function of
electronic devices such as the NanoChip(R) array, allowing the attachment and
immobilization of nucleic acids, which can serve as probes for detecting
nucleic acid sequences of interest, on the chip. The permeation layer allows
the diffusion of ions that balance the electric charge near the reaction site
and the precise electronic control of analyte movement, both of which
facilitate the rapid movement of nucleic acids to and from various test sites
on the NanoChip(R). The permeation layer also separates the attached
biomolecules from the electrochemical environment generated immediately at the
electrode, preventing the attached molecule's exposure to the highly reactive
surface, which can rapidly destroy nucleic acids or other biomolecules.
"Nanogen's electronic microarray platform includes many cutting-edge
inventions, each of which contributes to the unique performance
characteristics of our instrument system for molecular testing," said Howard
C. Birndorf, Nanogen chairman and chief executive officer. "Each patent we
secure will further protect our investment in the development of products like
the NanoChip(R) array."
About Nanogen, Inc.
Nanogen's advanced technologies provide researchers, clinicians and
physicians worldwide with improved methods and tools to predict, diagnose, and
ultimately help treat disease. The company's products include real-time PCR
reagents, the NanoChip(R) electronic microarray platform and a line of rapid
diagnostic tests. Nanogen's ten years of pioneering research involving
nanotechnology holds the promise of miniaturization and continues to be
supported for its potential for diagnostic and biowarfare applications. For
additional information please visit Nanogen's website at www.nanogen.com.
This press release contains forward-looking statements that are subject to
risks and uncertainties that could cause actual results to differ materially
from those set forth in the forward-looking statements, including whether
patents owned or licensed by Nanogen will be developed into products, whether
the patents owned by Nanogen offer any protection against competitors with
competing technologies, whether products under development can be successfully
developed and commercialized, whether results reported by our customers or
partners can be identically replicated, and other risks and uncertainties
discussed under the caption "Factors That May Affect Results" and elsewhere in
Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date hereof. Nanogen disclaims any intent or obligation to update these
SOURCE Nanogen, Inc.